このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors (PRT-BC)

2026年11月6日 更新者:University of Michigan Rogel Cancer Center

A Single-Arm Pilot Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors

The goal of this study is to evaluate the feasibility, acceptability, and preliminary clinical effects of an oncology-adapted Pain Reprocessing Therapy (PRT) intervention for women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). AIMSS is a common complication of aromatase inhibitor therapy for estrogen receptor-positive breast cancer and is associated with chronic pain, functional impairment, and premature discontinuation of endocrine therapy. The study will evaluate whether a six-session, manualized PRT intervention delivered remotely by trained palliative care therapists is feasible to implement and shows preliminary evidence of improving pain and physical function.

調査の概要

研究の種類

介入

入学 (推定)

44

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Jonathan Song
  • 電話番号:734-615-1279
  • メール:wmsong@umich.edu

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • History of ductal carcinoma in situ (DCIS) or Stage I-III estrogen receptor-positive breast cancer.
  • Post-menopausal prior to starting AI or receiving luteinizing hormone-releasing hormone (LHRH) agonist therapy.
  • Currently taking aromatase inhibitor therapy - anastrozole, exemestane, or letrozole - for adjuvant treatment of breast cancer or for chemoprevention.
  • Current aromatase inhibitor therapy for at least 3 weeks and no more than 2 years prior to enrollment.
  • Diagnosis of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), defined as new or worsening joint pain and/or myalgias since starting aromatase inhibitor therapy,
  • Have had at least 3 months of recovery since the last invasive surgery
  • Adequate home internet access, defined as reliable access to a private internet connection or cellular data service that supports real time two-way audiovisual telehealth visits using the University of Michigan-approved video conferencing platform on a computer tablet or smartphone. Participants must be able to complete study telehealth visits from a private location.

Exclusion Criteria:

  • Evidence of active cancer or progression of disease on most recent imaging, confirmed with the treating oncologist.
  • Planned invasive surgery during Day 0-60, that could interfere with study participation, pain assessment, or functional outcomes.
  • Concurrent inflammatory arthropathy or autoimmune disorder.
  • Patient self-report or EMR documentation of moderate to severe memory impairment or a dementia diagnosis as these would interfere with the ability to understand and remember key elements of the intervention.
  • Current participation in cognitive behavioral therapy or other psychological therapy for pain, as concurrent pain-focused psychotherapy could confound interpretation of the effects of the study intervention. If they received psychotherapy in the past, they must be at least 30 days from their last session to enroll.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment Arm

PRT is a form of psychotherapy that incorporates pain neuroscience education (reframing chronic pain as a predominantly safe signal arising from the brain and nervous system rather than as something that only arises from damaged tissues) with mindfulness meditation and graded exposure strategies. . For this study, PRT has been adapted for the oncology and cancer survivorship context, and includes attention to cancer-related uncertainty, fear of recurrence, medical trauma, treatment-related bodily changes, and concerns about pain as a possible signal of cancer progression. The intervention is manualized and delivered over six sessions.

All participants will be asked only to participate in six 30-45 min intervention sessions. Participants will need to complete the sessions in the order specified. PRT will be delivered remotely by trained palliative care therapists using a HIPAA compliant secure video conferencing platform. Each session will last approximately 30-45 minutes. The intervention will be delivered in English only.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Recruitment - Number
時間枠:11 months of recruitment activity

Number of approached patients who consent to participate.

11 months of recruitment activity
Recruitment - proportion
時間枠:11 months of recruitment activity

Proportion of approached patients who consent to participate.

11 months of recruitment activity
Retention - Assessments completed
時間枠:180 days

Mean number of post intervention assessments completed per subject;

180 days
Retention - Proportion
時間枠:180 days

proportion of subjects completing the Day 60 and Day 180 assessments

180 days
Intervention Uptake: PRT Sessions count
時間枠:60 days

Mean number of PRT sessions attended per subject

60 days
Intervention Uptake: proportions of participants
時間枠:60 days

proportion completing at least 4 of 6 sessions and proportion completing all 6 sessions.

60 days
Representativeness:
時間枠:11 months of enrollment activity

The demographic and clinical characteristics of enrolled participants vs. those of potentially eligible patients identified from the University of Michigan Rogel Cancer Center source population during the recruitment period.

11 months of enrollment activity
Intervention fidelity.
時間枠:60 days of intervention

Intervention fidelity will be assessed through structured session checklists completed by interventionists after each visit, documenting delivery of required PRT components, session duration, and any deviations from the manual.

60 days of intervention
Acceptability of PRT intervention
時間枠:after 60 days of intervention

Treatment Acceptability and Adherence Scale (TAAS), a 10-item scale assessing perceived acceptability and usefulness of a behavioral intervention.(Milosevic et al., 2015) Scores above the midpoint - 35 out of 70 - will denote moderate acceptability of the intervention).

after 60 days of intervention
Participant satisfaction
時間枠:after 60 days of intervention

The CSQ-8 yields a total score ranging from 8 to 32, with higher scores indicating greater satisfaction.

after 60 days of intervention

二次結果の測定

結果測定
メジャーの説明
時間枠
Pain severity
時間枠:up to 180 days

Pain severity will be measured using a 0-10 Numeric Rating Scale (NRS) assessing average pain over the prior 7 days, with anchors of 0 ("no pain") and 10 ("worst pain imaginable") (Jensen et al., 1986).

up to 180 days
Change in Pain impact
時間枠:up to 180 days

Pain impact will be assessed using the Pain, Enjoyment of Life, and General Activity (PEG) scale, a validated 3-item composite measure of pain severity and pain-related interference (Keller et al., 2004; Krebs et al., 2010).

up to 180 days
Pain Interferece
時間枠:up to 180 days

Pain interference will be assessed using the PROMIS Pain Interference Short Form 6b, a 6-item measure evaluating the extent to which pain interferes with daily activities, social participation, and enjoyment of life over the past 7 days

up to 180 days
Physical Function T-scores
時間枠:up to 180 days

Physical function will be measured using the PROMIS Physical Function 4a, a validated 4-item patient-reported measure of physical functioning. Scores will be converted to standardized T-scores, with higher scores indicating better physical function

up to 180 days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Maria Silveira, MD、University of Michigan

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月30日

一次修了 (推定)

2029年2月1日

研究の完了 (推定)

2029年6月1日

試験登録日

最初に提出

2026年11月6日

QC基準を満たした最初の提出物

2026年11月6日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • UMCC 2026.079
  • U54AG0923230 (その他の助成金/資金番号:National Institutes of Health)
  • HUM00292989 (その他の識別子:University of Michigan Rogel Cancer Center)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Deidentified patient quantitative data and qualitative transcripts will be provided to a data repository at the University of Colorado which will gather the data on behalf of the National Institute of Aging.

IPD 共有時間枠

within 12 months of last participant completing study

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する